Why did BIT.AX stock drop so sharply intraday?

BIT.AX stock fell due to thin liquidity, elevated selling volume and limited near-term clinical catalysts. Negative EPS **-0.01**, potential dilution risk from fundraising and absence of a Phase II readout increased selling pressure on the ASX.

What are realistic price targets for BIT.AX stock?

Meyka AI models set a base 12-month target at **A$0.004** (+100.00%), a bear target **A$0.001** (-50.00%) and a bull target **A$0.006** (+200.00%). These are projections, not guarantees.

How should investors approach BIT.AX stock now?

Treat BIT.AX stock as speculative. Wait for clear Phase II trial updates or a favourable funding outcome. Use position sizing and expect high volatility on the ASX in AUD.

Where can I find official updates for Biotron Limited (BIT.AX)?

Monitor ASX announcements and the company website at https://www.biotron.com.au for official releases. Also track sector news and trading activity for liquidity signals.

AU Stocks

BIT.AX Biotron Limited ASX -33.33% intraday 05 Mar 2026: watch cash runway

ByDanny Kontos March 5, 2026

BIT.AX stock slid 33.33% intraday to A$0.002 on 05 Mar 2026, ranking it among the ASX top losers as volume surged to 7,400,440 shares. We see the move tied to thin liquidity, negative recent earnings metrics and limited near-term clinical catalysts for Biotron Limited (BIT.AX) on the ASX. Investors should weigh EPS -0.01, PE -0.25, and a market cap of roughly A$4,106,998.00 against trial timelines and funding needs. This intraday sell-off increases volatility but sharpens the focus on cash runway and upcoming trial updates